SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the China Food and Drug Administration has approved the company’s SureScan Dx microarray scanner as a medical device for in vitro diagnostic use. “Bringing microarray scanning technology to clinical-quality standards is an important milestone in moving the advancement of genome-wide chromosome analysis to the clinic,” said Dr. Richard Choy, associate professor at the Chinese University of Hong Kong. “